FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 77378

News■ Unclear/unknown

Jocasta Neuroscience and Diamond Therapeutics Announce Research Program to Explore Non-Hallucinogenic Psychedelic-Inspired Compounds for Cognitive Impairment and Neurodegeneration

Jocasta Neuroscience and Diamond Therapeutics Announce Research Program to Explore Non-Hallucinogenic…
EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A joint research program on psychedelic-inspired compounds is preclinical-stage and years from any regulatory or revenue event.

Early neuro research, long timeline
CATALYST TO WATCH

IND filing or trial initiation

MAIN RISK

Preclinical failure risk, no timeline

FULL DISPATCH

Joint research program will evaluate three novel compounds designed to replicate psilocybin's therapeutic effects SCOTTSDALE, Ariz., Oct. 13, 2026 /PRNewswire/ -- Jocasta Neuroscience, Inc. ("Jocasta" or "the Company") and Diamond Therapeutics Inc. ("Diamond Therapeutics") today announced...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-13 11:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.